Cover Image
市場調查報告書

癌症免疫療法交易趨勢:2011∼2015年

Immuno-Oncology Deal Trends, 2011-15

出版商 Datamonitor Healthcare 商品編碼 363586
出版日期 內容資訊 英文 58 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症免疫療法交易趨勢:2011∼2015年 Immuno-Oncology Deal Trends, 2011-15
出版日期: 2016年03月16日 內容資訊: 英文 58 Pages
簡介

癌症免疫療法,是可能戲劇性改變癌症治療方法的醫療新領域。對大型及中堅的製藥公司,推進行著重該領域的契約締結。

本報告提供癌症免疫療法交易趨勢的相關調查,過去5年的癌症免疫療法交易趨勢與成長,主要企業,最有影響力的企業導入的策略等相關彙整。

摘要整理

癌症免疫療法:概要

  • 癌症免疫療法、產業界、學術界,及政府採取複合性的舉措
  • 參考文獻

癌症免疫療法交易趨勢

  • 癌症免疫療法的交易額戲劇性地增加
  • Bristol-Myers Squibb和Merck & Co是龍頭企業
  • 癌症免疫療法佔癌症領域整體交易額的大部分
  • 特別是肺癌和黑色素瘤等的固態腫瘤領導交易
  • 非何杰金氏淋巴瘤和骨髓瘤在整體佔有率中減少
  • PD-L1/PD-1壟斷
  • 癌症免疫療法依標的改變
  • 參考文獻

癌症免疫療法的組合:聯合趨勢

  • 並用癌症免疫療法交易的牽引力
  • 並用聯合獨自的特性
  • 並用聯合
  • 參考文獻

癌症免疫療法交易的案例研究

  • AstraZeneca並用和在血液癌症中對durvalumab有高期待
  • Bristol-Myers Squibb試圖擴大癌症免疫療法的領導力
  • Celgene正試圖影響血液腫瘤
  • GlaxoSmithKline摸索著替代性標的
  • Merck & Co依靠和Keytruda的組合
  • Roche的atezolizumab在膀胱癌進化重要的是並用和PD-L1標靶化
  • 參考文獻

附錄

目錄
Product Code: DMKC0154383

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated. The Big Pharma and Mid Pharma peer sets are an integral part of development and have been furthering efforts via deal-making. The peer groups' deal volume in immuno-oncology has grown over sevenfold from 2011 to

2015. More than 50% of the immuno-oncology deals between 2011 and 2015 involved testing combinations that may eventually address previously unresponsive patients and/or additional tumor types. Combination agreements are structured differently to traditional licensing deals and are often pre-competitive in nature, early stage, and involve only one or two single studies.

This report addresses the following questions:

  • What is the growth of immuno-oncology deal-making over the last five years in volume and dollar value, and how does that compare with overall oncology deal-making?
  • Who are the top players in immuno-oncology deal-making, and what were the structures of their key deals?
  • Which solid and hematological tumor indications and anticancer immunotherapy targets are most involved immuno-oncology deals?
  • What strategies are being implemented by some of the most influential companies in immuno-oncology?

TABLE OF CONTENTS

EXECUTIVE SUMMARY

IMMUNO-ONCOLOGY: A BRIEF INTRODUCTION

  • 1. Immuno-oncology has sparked multiple industry, academic, and government initiatives
  • 2. Bibliography

KEY TRENDS IN IMMUNO-ONCOLOGY DEAL-MAKING

  • 3. Immuno-oncology deal volume has rapidly increased
  • 4. Bristol-Myers Squibb and Merck & Co were the top immuno-oncology dealmakers
  • 5. Immuno-oncology represented most of the overall oncology deal value
  • 6. Solid tumors, especially lung cancer and melanoma, led immuno-oncology deals
  • 7. Non-Hodgkin's lymphoma and myeloma decreasing in overall share of deals
  • 8. PD-L1/PD-1 dominated immuno-oncology deals
  • 9. Immuno-oncology targets vary across indications
  • 10. Bibliography

IMMUNO-ONCOLOGY COMBINATIONS: COLLABORATIVE EFFORTS

  • 11. Combinations are the driving force in immuno-oncology deal-making
  • 12. Combination collaborations have unique characteristics
  • 13. Combination collaborations
  • 14. Bibliography

IMMUNO-ONCOLOGY DEAL-MAKING CASE STUDIES

  • 15. AstraZeneca has high hopes for durvalumab in combinations and in hematological cancers
  • 16. Bristol-Myers Squibb aims to extend immuno-oncology leadership
  • 17. Celgene is trying to make an impact in hematological cancers
  • 18. GlaxoSmithKline looks to alternative immuno-oncology targets
  • 19. Merck & Co is banking on Keytruda combinations
  • 20. Roche's atezolizumab advances in bladder cancer, but combinations and non-PD-L1 targets are of importance
  • 21. Bibliography

APPENDIX

  • 22. Scope
  • 23. Methodology
Back to Top